Epidemiology and Management Challenges in Prolactinomas

Neuroendocrinology

Volumn 109, Issue 1, 2019, Pages 20-27

  Vroonen, Laurent ^a   Daly, Adrian F ^a   Beckers, Albert ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Dopamine agonist; Epidemiology; Genetics; Pediatrics; Prolactinoma; Resistance

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

AGED; ARTICLE; DRUG SAFETY; HUMAN; PEDIATRIC PATIENT; POPULATION; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; TUMOR RESISTANCE; FEMALE; HYPOPHYSIS TUMOR; MALE;

FEMALE; HUMANS; MALE; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 85066858095     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000497746     Document Type: Article

References (74)

1. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet. 1998 Oct; 352(9138): 1455-61.
2. Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol (Oxf). 2017 Jan; 86(1): 60-7.
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006 Dec; 91(12): 4769-75.
4. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a communitybased, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010 Mar; 72(3): 377-82.
5. Fontana E, Gaillard R. [Epidemiology of pituitary adenoma: results of the first Swiss study]. Rev Med Suisse. 2009 Oct; 5(223): 2172-4.
6. Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013 Dec; 16(4): 545-53.
7. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994 May; 120(10): 817-20.
8. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004 Aug; 101(3): 613-9.
9. Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006 May; 154(5): 753-8
10. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010 Sep; 95(9): 4268-75
11. Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, Filipsson Nyström H. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol. 2014 Oct; 171(4): 519-26
12. Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015 Nov; 173(5): 655-64
13. Day PF, Loto MG, Glerean M, Picasso MF, Lovazzano S, Giunta DH. Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch Endocrinol Metab. 2016 Nov-Dec; 60(6): 554-61
14. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf). 1994 Sep; 41(3): 359-64
15. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003 Mar; 148(3): 325-31
16. Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, et al. Estimated age-and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009 Aug; 94(8): 2729-34
17. Burdman JA, Pauni M, Heredia Sereno GM, Bordón AE. Estrogen receptors in human pituitary tumors. Horm Metab Res. 2008 Aug; 40(8): 524-7
18. Stefaneanu L, Kovacs K, Horvath E, Lloyd RV, Buchfelder M, Fahlbusch R, et al. In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. J Clin Endocrinol Metab. 1994 Jan; 78(1): 83-8
19. Maheux R, Jenicek M, Cleroux R, Beauregard H, De Muylder X, Gratton NM, et al. Oral contraceptives and prolactinomas: a casecontrol study. Am J Obstet Gynecol. 1982 May; 143(2): 134-8
20. Testa G, Vegetti W, Motta T, Alagna F, Bianchedi D, Carlucci C, et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception. 1998 Aug; 58(2): 69-73
21. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med. 1994 May; 118(5): 562-5
22. Bisson JR, Chan KJ, Safer JD. Prolactin levels do not rise among transgender women treated with estradiol and spironolactone. Endocr Pract. 2018 Jul; 24(7): 646-51
23. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type and type 2. J Clin Endocrinol Metab. 2001 Dec; 86(12): 5658-71
24. Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002 Feb; 87(2): 457-65
25. Daly AF, Beckers A. Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrinol Metab Clin North Am. 2015 Mar; 44(1): 19-25
26. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schurmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Montanana CF, Hana V, Halaby G, Delemer B, Aizpun JI, Sonnet E, Longas AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011 Oct; 165(4): 509-15
27. Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab. 2015 May; 100(5):E710-9
28. Daly AF, Castermans E, Oudijk L, Guitelman MA, Beckers P, Potorac I, et al. Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocr Relat Cancer. 2018 May; 25(5):L37-42
29. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005; 8(1): 3-6
30. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, et al.; Clinical Presentation and Long-Term Follow-Up. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab. 1998 Aug; 83(8): 2777-80
31. Fideleff HL, Boquete HR, Suárez MG, Azaretzky M. Prolactinoma in children and adolescents. Horm Res. 2009; 72(4): 197-205
32. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. 1999 Dec; 84(12): 4317-23
33. Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenický P, Bouligand J, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015 Mar; 100(3): 1177-86
34. Hoffmann A, Adelmann S, Lohle K, Claviez A, Müller HL. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur J Pediatr. 2018 Jan; 177(1): 125-32
35. Delgrange E, Duprez T, Maiter D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf). 2006 Apr; 64(4): 456-62
36. Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014 Dec; 47(3): 889-94
37. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001 Mar; 54(3): 295-300
38. Kovacs K, Ryan N, Horvath E, Singer W, Ezrin C. Pituitary adenomas in old age. J Gerontol. 1980 Jan; 35(1): 16-22
39. Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011 Dec; 25(6): 885-96
40. Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab. 2013 Jan; 98(1): 372-9
41. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996 Apr; 14(4): 228-38
42. Divers WA Jr, Yen SS. Prolactin-producing microadenomas in pregnancy. Obstet Gynecol. 1983 Oct; 62(4): 425-9
43. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006 Aug; 27(5): 485-534
44. Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2011 May; 7(5): 267-78
45. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999 Jul; 84(7): 2518-22
46. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001 Nov; 86(11): 5256-61
47. Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012 Nov; 167(5): 651-62
48. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009 May; 160(5): 747-52
49. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005; 8(1): 43-52
50. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003 Nov; 349(21): 2023-33
51. Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary. 2015 Oct; 18(5): 745-51
52. Paepegaey AC, Salenave S, Kamenicky P, Maione L, Brailly-Tabard S, Young J, et al. Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. J Endocr Soc. 2017 Feb; 1(3): 221-30
53. Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005; 8(1): 53-60
54. Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine. 2017 Jan; 55(1): 223-30
55. Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012 May; 166(5): 779-86
56. Ma Q, Su J, Li Y, Wang J, Long W, Luo M, et al. The Chance of Permanent Cure for Microand Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2018 Oct; 9: 636
57. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med. 2005 Sep; 353(10): 1021-7
58. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008 Jul; 159(1): 1-5
59. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008 Oct; 159(4):R11-4
60. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009; 12(3): 153-7
61. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009 Jan; 70(1): 104-8
62. Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F, Zelissen PM. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010 Apr; 162(4): 667-75
63. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008 Oct; 93(10): 3777-84
64. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008 Sep; 93(9): 3348-56
65. Maione L, Garcia C, Bouchachi A, Kallel N, Maison P, Salenave S, et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab. 2012 Sep; 97(9):E1714-9
66. Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M, Colao A. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013 Aug 28; 169(3): 359-66
67. Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Marsan NA, Holman ER, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012 Jul; 77(1): 99-105
68. Vroonen L, Lancellotti P, Garcia MT, Dulgheru R, Rubio-Almanza M, Maiga I, et al. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine. 2017 Jan; 55(1): 239-45
69. Caputo C, Prior D, Inder WJ. The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening. J Endocr Soc. 2018 Jul; 2(8): 965-9
70. Noronha S, Stokes V, Karavitaki N, Grossman A. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine. 2016 Feb; 51(2): 205-10
71. Athanasoulia-Kaspar AP, Popp KH, Stalla GK. Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocr Connect. 2018 Feb; 7(2):R88-94
72. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015 Feb; 30(2): 121-7
73. Vriend C. The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks. Cell Tissue Res. 2018 Jul; 373(1): 327-36
74. Weintraub D, Papay K, Siderowf A; Parkinson's Progression Markers Initiative. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013 Jan; 80(2): 176-80.